Herantis Pharma Plc, Press Release, 2 May 2023 at 11:45 A.M. EEST
Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease, today announced that Herantis Pharma has been selected as presenting company with live presentation during the 23rd Bio€quity Europe Conference, in May 14-16, 2023 in Dublin.
CEO, Antti Vuolanto will give a company presentation:
May 16th at 11:39 AM EEST / 10:39 AM CET / 09:39 AM IST
Location: Liffey Meeting Room 3, Convention Centre Dublin
If you want 1×1 meetings with Herantis, you can contact the conference organizers or connect with us directly at firstname.lastname@example.org.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com